2024-2032 年按疾病类别、药物类别和地区分類的缺血性心臟病药物市场报告

2023年全球缺血性心臟病（IHD）药物IMARC Group规模达63亿美元。 。

缺血性心臟病 (IHD)，也称为冠心病，是一种透过中断氧气和血液供应来损害心肌的疾病。它涉及血管的分子变化或动脉粥状硬化引起的冠状动脉突然关闭和狭窄。这种疾病的特征通常是慢性胸痛和严重不适，如果不及时治疗可能致命。根据病例的严重程度，可以使用多种药物来治疗 IHD。例如，如果胆固醇调节药物降低血液中的胆固醇水平，则服用阿斯匹灵来减少血液的凝血倾向，并使用β受体阻断剂来降低心率和血压。 IHD 药物还包括钙通道阻断剂和雷诺嗪，可提高 β 阻断剂的效率并防止冠心病进一步进展。

大众对介入医疗手术的兴趣日益浓厚，以及抗心绞痛药物广泛用于治疗缺血性心臟病，是推动市场成长的关键因素之一。 IHD 药物正被纳入血管成形术、斑块旋切术和球囊血管成形术等心臟病治疗程序中，以确保健康康復并防止未来復发。此外，消费者对定期服用这些药物的好处的认识不断提高，也对他们的需求产生了重大影响。过度饮酒和吸烟等生活习惯以及缺乏身体活动也导致心血管疾病的盛行率不断增加。此外，全球患有心臟病的老年人口数量不断增加，也增加了对 IHD 药物的需求。

本报告回答的关键问题：

• 迄今为止，全球缺血性心臟病（IHD）药物市场表现如何，未来几年将如何表现？
• COVID-19 对全球缺血性心臟病 (IHD) 药物市场有何影响？
• 依疾病类别分類的市场是怎么样的？
• 根据药物类别分類的市场是怎么样的？
• 全球缺血性心臟病（IHD）药物产业的主要区域市场有哪些？
• 全球缺血性心臟病（IHD）药物产业价值链的各个阶段是什么？
• 全球缺血性心臟病（IHD）药物产业的关键驱动因素和挑战是什么？
• 全球缺血性心臟病（IHD）药物产业的结构如何？
• 全球缺血性心臟病（IHD）药物产业的竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

• 研究目的
• 利害关係人
• 资料来源
  • 主要资源
  • 二手资料
• 市场预测
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第 3 章：执行摘要

第 4 章：简介

• 概述
• 主要行业趋势

第 5 章：全球缺血性心臟病 (IHD) 药物市场

• 市场概况
• 市场业绩
• COVID-19 的影响
• 市场预测

第 6 章：市场区隔：依疾病类别

• 心绞痛
  • 市场走向
  • 市场预测
• 心肌梗塞
  • 市场走向
  • 市场预测

第 7 章：市场区隔：依药物类别

• 抗血脂异常药物
  • 市场走向
  • 市场预测
• 钙通道阻断剂
  • 市场走向
  • 市场预测
• β-受体阻断剂
  • 市场走向
  • 市场预测
• ACE抑制剂
  • 市场走向
  • 市场预测
• 血管张力素受体阻断剂
  • 市场走向
  • 市场预测
• 血管扩张剂
  • 市场走向
  • 市场预测
• 抗血栓剂
  • 市场走向
  • 市场预测

第 8 章：市场区隔：按地区

• 北美洲
  • 市场走向
  • 市场预测
• 欧洲
  • 市场走向
  • 市场预测
• 亚太地区
  • 市场走向
  • 市场预测
• 中东和非洲
  • 市场走向
  • 市场预测
• 拉丁美洲
  • 市场走向
  • 市场预测

第 9 章：SWOT 分析

• 概述
• 优势
• 弱点
• 机会
• 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

• 概述
• 买家的议价能力
• 供应商的议价能力
• 竞争程度
• 新进入者的威胁
• 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co.
  • Eisai Co., Ltd.

The global ischemic heart disease (IHD) drugs market size reached US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.9% during 2024-2032.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:

Angina Pectoris

Myocardial Infarction

Breakup by Drug Class:

Anti-Dyslipidemic Drugs

Calcium Channel Blockers

Beta-Blockers

ACE Inhibitors

ARBs

Vasodilators

Antithrombotic Agents

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:

• How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
• What is the breakup of the market based on the disease class?
• What is the breakup of the market based on the drug class?
• What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
• What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
• What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
• What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
• What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Ischemic Heart Disease (IHD) Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Class

• 6.1 Angina Pectoris
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Myocardial Infarction
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Anti-Dyslipidemic Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Calcium Channel Blockers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Beta-Blockers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 ACE Inhibitors
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 ARBs
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Vasodilators
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Antithrombotic Agents
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Bayer AG
  • 13.3.2 Eli Lilly and Company
  • 13.3.3 Novartis International AG
  • 13.3.4 Pfizer, Inc.
  • 13.3.5 Sanofi S.A.
  • 13.3.6 Actelion Pharmaceuticals Ltd.
  • 13.3.7 Baxter International Inc.
  • 13.3.8 Boehringer Ingelheim International GmbH
  • 13.3.9 Bristol-Myers Squibb Company
  • 13.3.10 Amgen Inc.
  • 13.3.11 F. Hoffmann-La Roche AG
  • 13.3.12 GlaxoSmithKline Plc
  • 13.3.13 Merck & Co.
  • 13.3.14 Eisai Co., Ltd.

List of Figures

• Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2023
• Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2023
• Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2023
• Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
• Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
• Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million US$), 2024-2032
• Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
• Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: Ischemic Heart Disease Drugs Market: Competitive Structure
• Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players